October 6, 2017

Amicus Therapeutics Appoints Michael C. Diem, MD as Senior Vice President of Business and Corporate Development

October 4, 2017

Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at World Muscle Society

September 21, 2017

U.S. FDA Grants Orphan Drug Designation for ATB200/AT2221 for Pompe Disease